[1]CurrentPatentAssignee:ORIONOYJ-WO2011/51540,2011,A1Locationinpatent:Page/Pagecolumn51
[2]Denner,Karsten;Gieschen,Hille;Jungmann,NataliaA.;Kähkönen,Marja;Korjamo,Timo;Koskinen,Mikko;Niehues,Michael;Nykänen,Pirjo;Prien,Olaf;Taavitsainen,Päivi;VonBühler,Clemens-Jeremias;Vuorela,Annamari;Zurth,Christian[DrugMetabolismandDisposition,2021,vol.49,#6,p.420-433]
[1]CurrentPatentAssignee:ORIONOYJ-WO2011/51540,2011,A1Locationinpatent:Page/Pagecolumn65-66
[1]CurrentPatentAssignee:THERAVANCEBIOPHARMA,INC.-US2012/157383,2012,A1Locationinpatent:Page/Pagecolumn44
[1]CurrentPatentAssignee:THERAVANCEBIOPHARMA,INC.-US2012/157383,2012,A1Locationinpatent:Page/Pagecolumn44
[1]CurrentPatentAssignee:ORIONOYJ-WO2016/162604,2016,A1Locationinpatent:Page/Pagecolumn16;17
[2]Yu,Jiang;Zhou,Peiting;Hu,Mingxing;Yang,Liuqing;Yan,Guoyi;Xu,Ruixue;Deng,Yufang;Li,Xinghai;Chen,Yuanwei[EuropeanJournalofMedicinalChemistry,2019,vol.182]
[3]CurrentPatentAssignee:ORIONOYJ-WO2012/143599,2012,A1Locationinpatent:Page/Pagecolumn71
Title: Agonist lead identification for the high affinity niacin receptor GPR109a.
Journal: Bioorganic & medicinal chemistry letters 20070901